Literature DB >> 6667061

Effects of buflomedil on isolated dog arteries.

N Toda, H Okunishi, T Okamura, M Miyazaki.   

Abstract

Buflomedil (10(-6) to 10(-4) M) relaxed, in a concentration-dependent manner, helical strips of dog mesenteric, renal and femoral arteries, partially contracted due to previous exposure to noradrenaline. When partial contraction was caused by prostaglandin F2 alpha, Buflomedil produced a slight relaxation of the mesenteric and coronary arterial strips, had no effect in cerebral and femoral arteries and caused a small contraction of renal arterial strips. Buflomedil did not reduce contractions induced by submaximal concentrations of K+ in normal media and those induced by Ca++ in mesenteric arteries exposed to Ca++-free media and depolarized by excess K+. Contractile responses to transmural electrical stimulation and exogenous noradrenaline were attenuated by buflomedil; the attenuations in femoral and mesenteric arteries did not differ. Protection against persistent blockade of alpha-adrenoceptors by phenoxybenzamine was obtained by pretreatment of mesenteric arteries with buflomedil. Relaxant responses of cerebral and coronary arteries to nicotine were suppressed or abolished by buflomedil, whereas the relaxation of coronary arteries induced by tyramine was unaffected or reduced only slightly. It is concluded that buflomedil reversibly blocks alpha-adrenoceptors in arterial smooth muscle and possesses an anti-nicotinic action. As far as the concentrations used in the present study are concerned, buflomedil does not appear to interfere with the transmembrane influx of Ca++.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6667061

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  1 in total

Review 1.  Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases.

Authors:  S P Clissold; S Lynch; E M Sorkin
Journal:  Drugs       Date:  1987-05       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.